FDA Approves Brexafemme for Recurrent Vulvovaginal Candidiasis
Brexafemme is an oral antifungal agent representing a novel therapeutic class of structurally-distinct glucan synthase inhibitors known as triterpenoids.
Diagnosis & Disease Information
Ibrexafungerp Under Review for Prevention of Recurrent Vulvovaginal Candidiasis
The sNDA is supported by data from the phase 3 CANDLE study.
Solosec Approval Expanded to Adolescents With Bacterial Vaginosis, Trichomoniasis
The overall safety findings of Solosec in pediatric patients were consistent with those observed in adult patients.
Clindamycin Vaginal Gel Gets Priority Review for Bacterial Vaginosis
The product is designed as a one-time vaginally administered treatment.
Oteseconazole Gets Priority Review for Recurrent Vulvovaginal Candidiasis
The NDA submission is supported by data from three phase 3 trials, which included 2 global studies and one US-focused study.
- Loading...
Loading...
Loading... 
Loading...